medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2008, Number 2

<< Back Next >>

Rev Mex Patol Clin Med Lab 2008; 55 (2)

Frequency and distribution of genotypes of hepatitis C vitus in selected Mexican population

Márquez-Rosales MG, Santoscoy-Tovar FA, Héctor Montoya-Fuentes

Language: Spanish
References: 31
Page: 79-87
PDF size: 150.48 Kb.


ABSTRACT

Introduction: Hepatitis C virus is the main cause of post-transfusional hepatitis. Because it is considered as a public health problem, its transcendental to estimate the frequency and distribution of hepatitis C genotype in our country, in order to obtain a better epidemiological profile for each genotype in Mexican population. Methods: 403 samples were analyzed from hepatitis C patients of Unidad de Patología Clínica. The genotype was obtained by means of LiPA, viral load was estimated with COBAS AMPLICOR test and the statistical analysis with EBM calculator program. Results: 60% of patients were women and 39.7% men. The genotype frequencies were: 58.3% type 1, 30.5% type 2, 8.7% type 3, 1% type 4, 1.5% mix types. The frequencies of subtypes were: 1b 26.8%, 1a 21.3%, 2a/2c 12.4%, 2b 9.2%, 3a 8.4%. The distribution of genotype by region of the country was: north n = 43 1b 46%, 1a 18.6%, 2a/2c 9.3%, 2b 7%; west and central n = 345 1b 24.1%, 1a 20.9 %, 2a/2c 13.3%, 2a 9.6%, 3a 9.6%; south n = 15 1a 40%, 1b 33%, 1a/1b 20%, 2b 7%. In 289 patients the viral load was: 69% within linear range (average 314,375 UI/mL) and the 31% greater than the upper limit, with viral load › 700,000 UI/mL. Conclusion: The 1b genotype was the most frequent. This study showed different VHC genotype frequencies within the country, besides against other populations, which the predominant genotypes are mainly 2a/2c.


REFERENCES

  1. Choo QL, Kuo G, Weiner AJ, Overby LR, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.

  2. Chang KM, Rehermann B, Chesori Francis V. Immunopathology of hepatitis C. Springier Semin. Immunopathology 1997; 19: 57-68.

  3. World Health Organization. Weekly Epidemiol Rec 1999; 74 (49): 425-427

  4. Gómez-Cordero I, Álvarez-García M. Biología y métodos diagnósticos del virus de hepatitis C. Rev Biomed 2003; 14: 253-268.

  5. Virus de las hepatitis. En: Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. (eds). Microbiología médica. 4a ed. Madrid, España: Elsevier, 2002: 592-593.

  6. Simmonds P, Alberti A, Alter HJ et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19 (5): 1321-1324.

  7. Halfon P, Roubicek C, Gerolami V, Quentin Y, Khiri H et al. Use of phylogenetic analysis of hepatitis C virus (HCV) hypervariable region 1 sequences to trace an outbreak of HCV in an autodialysis unit. J Clin Microbiol 2002; 40 (4): 1541-1545.

  8. Zein N. Clinical significance of hepatitis C virus genotypes. Rev Clin Microbiol 2000; 13 (2): 223-235.

  9. COBAS AMPLICOR HCV Monitor Test version 2.0. Roche Diagnostics. Braunchburg, NJ, USA. Revision 5.0 2003.

  10. Versant HCV Genotype Assay (LiPA). Bayer HealthCare. Tarrytown, NY, USA. Ref 128445, Rev. 1 2004-08.

  11. Haldane JBS. The estimation and significance of the logarithm of a ratio of frequencies. Ann Hum Genet 1955; 20: 309-311.

  12. Vicentellia R, Ovalles R et al. Seroprevalence of anti-VHC in patients attend at Clinic Immunology Regional Unit of Maracay, Venezuela, 2003-2004. Rev Soc Ven Microbiol 2005; 25 (2): 105-108.

  13. Colina R, Mogdasy MC, Cristina J, Uriarte MR. Caracterización molecular del virus de la hepatitis C en Montevideo-Uruguay. Rev Med Uruguay 2002; 18: 76-82.

  14. Valdés J, Rodríguez O, Cardellá R. Hepatitis C I. Frecuencia de seropositivos al VHC en los diferentes servicios del Hospital «Calixto García» en el trienio 1996-1998. Rev Cubana Invest Biomed 2004; 23 (4): 201-2018.

  15. Vilar-Gomez E, Grá-Oramas B, Llanio-Navarro R et al. Influencia de factores epidemiológicos en la progresión de la fibrosis en la hepatitis crónica C. Rev Cub Med 2003; 42 (5): ISSN 0034-7523.

  16. Arora DR, Sehgal R, Gupta N, Yadav A, Mishra N, Siwach SB. Prevalence of parenterally transmitted hepatitis viruses in clinically diagnosed cases of hepatitis. Ind J Med Microbiol 2005; 23 (1): 44-47.

  17. Vera LL y cols. Panorama epidemiológico y situacional de la hepatitis C en México. Rev Gastroenterol Mex 2005; 70 (1): 25-32.

  18. Méndez-Sánchez N et al. Hepatitis C virus genotypes in Mexico City. Journal of Hepatology 2002; 36 (1): 241.

  19. Sanchez JL, Sjogren MH, Callahan JD, Watts DM, Lucas C et al. Hepatitis C in Peru: risk factors for infection, potential iatrogenic transmission, and genotype distribution. Am J Trop Med Hyg 2000; 63 (5): 242-248.

  20. Mutchnick B, Klion T et al. Assessment of hepatitis C virus RNA and genotype from 6,807 patients with chronic hepatitis C in the United States. J Viral Hepatitis 2000; 7 (3): 196-202.

  21. Fernández-Salazar LI, Álvarez-Gago T et al. Iron overload and genotype 3 are associated with liver steatosis in chronic hepatitis C. Rev Esp Enferm Dig 2004; 96 (12): 818-828.

  22. Guadagnino V, Stroffolini T, Rapicetta M et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: A community-based survey in southern Italy. American Association for the Study of Liver Diseases. 1997; 26 (4): 1006-1011.

  23. Alvarez-Muñoz MT, Vences-Aviles MA, Vazquez-Rosales G et al. Hepatitis C virus RNA (HCV-RNA) in blood donors and family members seropositive for anti-VHC antibodies. Arch Med Res 2001; 32 (5): 442-445.

  24. Soza A, López-Lastra M. Hepatitis C en Chile: Magnitud del problema. Rev Med Chile 2006; 134: 777-788.

  25. Sy T, Jamal M. Epidemiology of Hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3 (2): 41-46.

  26. Zein N, Rakela J et al. Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to interferon therapy. Ann Inter Med 1996: 125 (8): 634-639.

  27. Zein N, Persing D. Hepatitis C genotypes: Current trends and future implications. Mayo Clin Proc 1996; 71: 458-462.

  28. Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, Coste J et al. Hepatitis C virus genotypes in France: Relationship with epidemiology, pathogenicity and response to interferon therapy. J Viral Hepatitis 1999; 6 (6): 435-443.

  29. Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, Pellet C et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis 1995; 171 (6): 1607-1610.

  30. 30.Córdoba J, Olaso V, Molina JM, López B et al. Análisis comparativo de la carga viral mediante bDNA HCV RNA-2.0 y Amplicor HCV Monitor, en pacientes infectados por el virus de la hepatitis C. Enf Infec Microbiol Clin 2000; 18 (1): 6-11.

  31. Nainan O, Alter MJ, Moran-Kruszon D et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 2006; 131 (2): 478-484.




2020     |     www.medigraphic.com